Silicone Breast Implant Approvals Conditioned On Huge Postmarket Studies
This article was originally published in The Gray Sheet
Executive Summary
FDA's Nov. 17 approval of silicone-gel breast implants comes with the requirement for one of the largest post-approval studies ever called for by the device center, according to CDRH Director Dan Schultz
You may also be interested in...
Study Highlights Autoimmune, CTD Issues In Women Who Had Breast Implants
Early results of a new study of 300 women who previously had breast implants, and a review of longer-term follow-up of patients who had their implants removed, found more patients have suffered autoimmune issues and connective tissue disease than have come out in FDA-mandated studies, according to the National Center for Health Research. NCHR was critical of FDA's and industry's approach to post-market surveillance of breast implants.
New Products In Brief
Abbott earns approval for a hepatitis C genotyping test. EDAP gets CE mark for its robotic HiFU prostate cancer device. More product news.
FDA Announces Possible Link Between Breast Implants And Cancer
In response to data suggesting that breast implants may be associated with a rare form of cancer, FDA plans to work with manufacturers on revised product labeling, the agency announced Jan. 26.